Solid-Phase Peptide Synthesis: How Research Peptides Are Made

Almost every research peptide on a lab bench began as a single amino acid fixed to a polymer bead. Solid-phase peptide synthesis (SPPS), introduced by R. Bruce Merrifield in 1963, turned peptide chemistry from a months-long solution-phase exercise into a repetitive, automatable loop of deprotection, washing and coupling. Understanding how SPPS works explains much of what appears on a certificate of analysis: why purity is rarely 100%, which impurities show up, and why the product is usually a salt. This overview walks through the chemistry step by step and uses the tripeptide KPV as a compact worked example.

The core idea of solid-phase peptide synthesis

The C-terminal amino acid is attached to an insoluble resin. Each subsequent amino acid, protected at its N-alpha amine and on any reactive side chain, is activated and coupled to the free amine of the growing chain. Because the peptide stays bound to the resin, excess reagents and by-products are removed simply by washing and filtering. Only at the end is the finished chain cleaved from the support and its side-chain protecting groups removed.

Today the dominant variant is Fmoc/tBu chemistry [1]. The temporary N-alpha Fmoc group is base-labile, while side-chain groups such as tert-butyl (tBu), trityl (Trt), Boc and Pbf are acid-labile. That orthogonality lets each Fmoc be removed repeatedly without touching the side chains, which come off together at final cleavage [3].

Choosing a resin and linker

The resin determines the C-terminal chemistry of the product:

Resin / linker	C-terminus produced	Notes
Wang	Free carboxylic acid	Classic choice for C-terminal acids
2-Chlorotrityl chloride (2-CTC)	Free acid, or protected fragments under mild acid	Bulky linker suppresses diketopiperazine formation
Rink amide	C-terminal amide	Standard for amidated peptides

Polystyrene cross-linked with divinylbenzene is common, and PEG-modified polystyrene resins swell better in polar solvents, which helps with difficult sequences [2].

One synthesis step, in detail

Each residue is added by the same sequence of operations [2]:

1. Fmoc removal with 20% piperidine in DMF, typically two treatments of a few minutes each. The dibenzofulvene by-product can be monitored by UV to follow deprotection.
2. Washing with DMF to remove piperidine.
3. Activation and coupling of the next Fmoc-amino acid, usually 3 to 5 equivalents, with a coupling reagent such as HBTU or HATU plus a base (DIPEA), or a carbodiimide such as DIC with an additive like Oxyma. Couplings commonly run 30 to 60 minutes.
4. Washing again.
5. Completion check, for example a ninhydrin (Kaiser) test for residual free amines, with recoupling or acetyl capping if needed.

Efficiency compounds. If each coupling is 99% complete, a 20-residue peptide assembled over 19 couplings gives roughly 0.99^19, or about 83%, full-length chains before any other losses. At 99.5% per step the figure rises to about 91%. This arithmetic is why deletion sequences are the most common impurity class in synthetic peptides [4].

Cleavage, precipitation and purification

When assembly is complete, the peptide-resin is treated with a cleavage cocktail, typically about 95% trifluoroacetic acid with scavengers such as water and triisopropylsilane (and ethanedithiol for cysteine-containing sequences) for 1 to 3 hours. Scavengers trap the reactive carbocations released from protecting groups, which would otherwise alkylate tryptophan, methionine, tyrosine or cysteine [3].

The crude peptide is precipitated in cold diethyl ether, washed and dried, then purified by preparative reversed-phase HPLC on C18 with water/acetonitrile gradients containing 0.1% TFA. Fractions are checked by analytical HPLC and mass spectrometry, pooled and lyophilized. The purified product is therefore usually a trifluoroacetate salt; exchange to acetate or hydrochloride requires an extra step. How the analytical checks work is covered in HPLC purity testing and mass spectrometry identity confirmation.

Side reactions and where impurities come from

SPPS side reactions map directly onto the impurities found in finished peptides [4]:

• Deletions from incomplete coupling or incomplete Fmoc removal.
• Insertions from excess activated amino acid or premature Fmoc loss.
• Racemization during activation, especially at cysteine and histidine, giving diastereomers with identical mass.
• Aspartimide formation, in which an Asp side chain cyclizes onto the backbone under the basic deprotection conditions, most readily at Asp-Gly; the ring can reopen to beta-aspartyl peptides or piperidides [1].
• Diketopiperazine (DKP) formation at the dipeptide stage, where the free amine attacks the resin ester and cleaves a cyclic dipeptide, notably when proline is the second residue from the C-terminus.
• Incomplete side-chain deprotection or scavenger adducts after cleavage.
• Aggregation of the growing chain on the resin, the main cause of failed "difficult sequences"; pseudoproline and depsipeptide building blocks disrupt the hydrogen bonding behind it [2].

These impurity classes, and what they mean for purity figures, are discussed in peptide purity grades explained.

Short sequences are not automatically easy: the KPV case

KPV is the tripeptide Lys-Pro-Val (342.4 Da as the free acid), the C-terminal sequence of alpha-melanocyte-stimulating hormone. It has been studied as a substrate of the di/tripeptide transporter PepT1: in cultured human intestinal epithelial and immune cells, and in murine colitis models, PepT1-mediated uptake of KPV was reported to reduce inflammatory signalling [5]. Later work in PepT1-overexpressing and PepT1-deficient mice examined the same transporter in a colitis-associated cancer model [6].

As a synthesis target, KPV is short but not trivial, and it illustrates two general points.

Proline near the C-terminus invites diketopiperazine formation. With proline as the second residue from the C-terminal end, the dipeptide stage is the most vulnerable moment in the whole assembly: the newly freed amine can attack the ester bond holding the chain to the resin, cutting a cyclic dipeptide loose and stranding the synthesis. This is a well-documented loss pathway rather than a subtle one, and it is the reason bulky linkers such as 2-chlorotrityl are preferred for sequences with proline or glycine in those positions [4].

Lysine needs side-chain protection. The lysine epsilon-amine is as nucleophilic as the alpha-amine, so it must be masked throughout assembly or it will branch the chain. Acid-labile protection is removed at final cleavage along with the linker [3].

The analytical consequences follow directly. For a tripeptide like this, an HPLC purity figure should be read with an eye on early-eluting peaks, because a short, basic, polar peptide is weakly retained on C18 and can sit close to unretained material. The identity check is straightforward: a monoisotopic mass of 342.23 Da and an [M+H]+ ion near m/z 343.23 for the free acid. Per-lot chromatograms and spectra for products like this are posted on our lab reports page.

What SPPS means for the material in your vial

Three practical points follow from the chemistry:

• Purity is inherited from the synthesis. Deletion sequences, diastereomers and protection adducts are by-products of the route, not signs of carelessness; purification reduces them but rarely removes them entirely.
• The salt form comes from the process. TFA cleavage and TFA-based preparative HPLC leave trifluoroacetate paired with basic residues unless an exchange step is added.
• Sequence predicts difficulty. Long, hydrophobic or aggregation-prone sequences, Asp-Gly motifs and C-terminal proline all raise the likelihood of characteristic impurities, which is useful context when reading a chromatogram.

Browse the catalogue on our shop page and each product lists the sequence and mass that these checks are made against.

Key takeaways

• SPPS builds peptides C-terminus to N-terminus on a solid support, with washing between steps replacing solution-phase purification.
• Fmoc/tBu chemistry is the modern standard: base-labile N-alpha protection, acid-labile side-chain protection, TFA cleavage at the end.
• Coupling efficiency compounds across steps, which is why deletion sequences are the most common impurity class.
• Aspartimide formation, racemization, diketopiperazine loss and on-resin aggregation are the main documented side reactions.
• The process explains the product: purity grade, impurity type and TFA salt form all trace back to synthesis and purification.

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. PubMed
2. Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247-3256. PubMed
3. Isidro-Llobet A, Alvarez M, Albericio F. Amino acid-protecting groups. Chem Rev. 2009;109(6):2455-2504. PubMed
4. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed
5. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PubMed
6. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. PubMed